Becton Dickinson and Co banner

Becton Dickinson and Co
NYSE:BDX

Watchlist Manager
Becton Dickinson and Co Logo
Becton Dickinson and Co
NYSE:BDX
Watchlist
Price: 148.72 USD -1%
Market Cap: $42.3B

EV/FCFF

22.2
Current
20%
Cheaper
vs 3-y average of 27.9

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
22.2
=
Enterprise Value
$68.3B
/
Free Cash Flow to Firm
$2.6B

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
22.2
=
Enterprise Value
$68.3B
/
Free Cash Flow to Firm
$2.6B

Valuation Scenarios

Becton Dickinson and Co is trading below its 3-year average

If EV/FCFF returns to its 3-Year Average (27.9), the stock would be worth $186.52 (25% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+25%
Average Upside
15%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 22.2 $148.72
0%
3-Year Average 27.9 $186.52
+25%
5-Year Average 27.9 $186.52
+25%
Industry Average 23 $154.1
+4%
Country Average 23.2 $155.37
+4%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
US
Becton Dickinson and Co
NYSE:BDX
42.8B USD 22.2 24.1
US
Intuitive Surgical Inc
NASDAQ:ISRG
167.2B USD 63.7 57.6
US
Abbott Laboratories
NYSE:ABT
161.2B USD 22.2 26
US
Stryker Corp
NYSE:SYK
125.8B USD 31.3 37.9
IE
Medtronic PLC
NYSE:MDT
106.4B USD 23.1 22.8
US
Boston Scientific Corp
NYSE:BSX
88.9B USD 26.2 24.3
US
Edwards Lifesciences Corp
NYSE:EW
48.5B USD 32.9 43.4
DE
Siemens Healthineers AG
XETRA:SHL
40.1B EUR 21.1 18.8
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.8B USD 43.8 42.8
US
Resmed Inc
NYSE:RMD
32.3B USD 17.2 21.3
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
32.1B USD 24.3 15.1

Market Distribution

In line with most companies in the United States of America
Percentile
48th
Based on 8 393 companies
48th percentile
22.2
Low
0 — 15.4
Typical Range
15.4 — 35.1
High
35.1 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 15.4
Median 23.2
70th Percentile 35.1
Max 3 178 983.5

Becton Dickinson and Co
Glance View

Founded in 1897, Becton Dickinson and Co., commonly known as BD, embarked on its journey with the vision to improve medical discovery and diagnostics. Over the decades, BD has transformed from a small syringe and needle manufacturer to a global leader in the medical technology industry. Situated in Franklin Lakes, New Jersey, BD has carved out a prominent place through its steadfast commitment to addressing health care workers' requirements and enhancing patient outcomes. The company's diversified portfolio spans across three major segments: BD Medical, BD Life Sciences, and BD Interventional. This trinity of divisions underscores BD's prowess in producing a broad range of medical supplies, laboratory equipment, and diagnostic products that find their way into hospitals, research facilities, and clinics worldwide. The company operates primarily by innovating and supplying products that are indispensable to everyday medical care and scientific research. BD’s robust revenue stream is bolstered by its strategic approach to integrating new technologies and acquiring innovative smaller companies that complement its core offerings. Through strategies like these, BD continuously adapts to the evolving healthcare landscape. Its products, such as advanced syringes, safety-engineered devices, and sophisticated laboratory equipment, are deeply embedded in the healthcare system, making BD a critical part of the global push for improved health outcomes. The company’s blend of consistent product demand and strategic innovations secures a stable financial footing, allowing it to invest further in research and development while extending its market reach across the globe.

BDX Intrinsic Value
228.74 USD
Undervaluation 35%
Intrinsic Value
Price $148.72
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett